The short version
Only one company currently supplies this market — there is no backup if it stumbles. It is in shortage right now.
Market view
dexmedetomidine hydrochloride in 0.9% sodium chloride · Injection, Solution
2 marketed package NDCs · 1 active manufacturer
Same drug class
Other molecules FDA puts in Central alpha-2 Adrenergic Agonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- dexmedetomidine hcl· in shortage
- dexmedetomidine· in shortage
- dexmedetomidine hydrochloride· in shortage
- clonidine hci· 1 maker
- clonidine hydrochloride oral· 1 maker
- dexmedetomidine hydrochloride in sodium chloride· 1 maker
- tizandine· 1 maker
- clonidine transdermal system· 2 makers
- guanfacine er· 2 makers
- tizanidine hcl· 2 makers
- gaunfacine· 3 makers
- methyldopa· 4 makers
Common questions
- Is Dexmedetomidine hydrochloride in 0.9% sodium chloride in shortage right now?
- Yes. FDA currently lists Dexmedetomidine hydrochloride in 0.9% sodium chloride in shortage. This page is rebuilt every morning from FDA's shortage database.
- Who makes Dexmedetomidine hydrochloride in 0.9% sodium chloride?
- 4 companies have marketed Dexmedetomidine hydrochloride in 0.9% sodium chloride in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
Shortage reports for this molecule
- In shortage now — Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)Apr 10, 2020
- In shortage now — Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)Apr 10, 2020
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.